Adenocarcinoma of the Gallbladder
6 clinical trials · Condition
◉ Watch Adenocarcinoma of the Gallbladder
| Record | Firm | Date |
|---|---|---|
| Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery (NCT01859182) | National Cancer Institute (NCI) | 2013-01-01 |
| Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery (NCT00478140) | National Cancer Institute (NCI) | 2007-05-01 |
| S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma (NCT00238212) | National Cancer Institute (NCI) | 2005-10-01 |
| Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder (NCT00085410) | National Cancer Institute (NCI) | 2004-01-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (NCT00028496) | National Cancer Institute (NCI) | 2001-11-01 |
Track Adenocarcinoma of the Gallbladder automatically
Every clearance here is in the API, with alerts when new ones post.